No content results match your keyword.
Content
You have successfully logged out.
Not registered yet?
No product results match your keyword.
Products
SeQuent® DCBs
Your way to confidence
Enter the world of SeQuent® DCB treatment with cutting-edge balloon technology and a proven leader at your side – for more drug options, more clinical data, high-quality support and the confidence you’re aiming for.
Cooperation
Cardiovascular News
New Momentum in DCB-PCI - Insights from B. Braun DCB Day
At the recent DCB Days nine esteemed DCB experts like Raban Jeger and Robert Byrne shared their key concepts and insights on the principle of leaving nothing behind in coronary vessels. The course covered key concepts and practical applications, allowing attendees to deepen their understanding and enhance their skills in this area.
Read articlePaclitaxel coated balloon
SeQuent® Please NEO – Master of evidence
SeQuent® Please NEO
Best Investigated DCB
-
> 0
published studies
-
> 0
documented patients
-
> 0
countries
Sirolimus coated balloon
SeQuent® SCB – Pioneer of proof
B. Braun´s new sirolimus coated balloon is the first SCB backed up with published randomized clinical trials for ISR and de-novo lesions. [2], [3], [4] SeQuent® SCB now offers new implant-free options for treating coronary ISR and de-novo lesions, providing excellent results in targeted drug delivery and sirolimus persistence. The combination of sirolimus and BHT (Butylated Hydroxy Toluol) creates the desired crystalline sirolimus modification to reach best results regarding sirolimus vessel wall content compared to other excipients. [5]
- SeQuent® SCB is the only coronary sirolimus coated balloon with published RCTs: 2 RCTs on ISR lesions, 1 RCT on de-novo lesions
- Multicenter data from Europe and Asia
- Ongoing studies for de-novo and real world
Randomized controlled trials
2020 | Primary Investigator: Jeger R | Study Aim: SQP vs. DES, Vessel: RD ≤ 3 mm | (Primary) Endpoint: MACE @ 36-month follow-up | Patients: 758
Summary BASKET-SMALL 22017 | Primary Investigator: Funatsu A | Study Aim: DCB vs. POBA, Vessel: RD ≤ 2.75 mm, ≥ 2 mm | (Primary) Endpoint: TVF @ 6-month follow-up | Patients: 135
Summary PEPCAD Japan SVD2017 | Primary Investigator: Gobić D | Study Aim: DCB vs. DES, Patients: STEMI (< 12 h) | (Primary) Endpoint: MACE, LLL @ 6-month follow-up | Patients: 75
Summary AMI Feasibility Study2016 | Primary Investigator: Nishiyama N | Study Aim: DCB vs. DES | (Primary) Endpoint: TLR @ 8-month follow-up | Patients: 60
Summary Clinical Value "Stent-less" PCINot randomized controlled trials & observational studies
2019 | Primary Investigator: Rosenberg M | Study Aim: DCB – ISR & De Novo | (Primary) Endpoint: TLR @ 9-month follow-up | Patients: 1,025
Summary DCB-only All-Comers Registry2016 | Primary Investigator: Shin E | Study Aim: DCB – De Novo, Vessel: RD ≤ 3.5 mm, ≥ 2.5 mm | (Primary) Endpoint: LLL, FFR @ 9-month follow-up, MI, TLR @ 12-month follow-up | Patients: 67
Summary FFR-Guided DCB-Angioplasty2014 | Primary Investigator: Zeymer U | Study Aim: DCB – De Novo, Vessel: RD ≤ 2.75 mm, ≥ 2.0 mm | (Primary) Endpoint: TLR @ 9-month follow-up | Patients: 447
Summary SVD Registry2023 | Primary Investigator: Shin ES | Study Aim: Investigate the impact of DCB-based treatment on PCI for multivessel CAD | (Primary) Endpoint: MACE @ 24-months (cardiac death, MI, TVR, stroke, stent thrombosis and major bleeding) | Patients: 508
Summary DCB-based PCI in Multi-Vessel-DiseasePreclinical work and randomized controlled trials
Sirolimus + BHT (Butylated Hydroxy Toluol): Persistence in the vessel wall
Read moreTwo RCTs for SeQuent® SCB vs. SeQuent® Please NEO with angiographic and clinical follow-ups.
Read summaryRCT for SeQuent® SCB vs. SeQuent® Please NEO with angiographic and clinical follow-ups.
Read summary
Related documents
-
SeQuent® Please NEO
Clinically proven drug coated balloon catheter
link
-
SeQuent® SCB
Sirolimus coated balloon catheter for PTCA
link
-
SeQuent® Please NEO – Go Implant-Free!
Safe and effective alternative to DES in de novo lesions
pdf, 27.8 KB
-
Cardiology Catalog
Your partner for coronary angioplasty
link
Get in touch with our Coronary Drug Coated Balloon experts
Contact usReferences
- All numbers referring to clinical coronary trials on PCBs, patients enrolled therein and countries in which these trials were conducted, are based on a PubMed literature search conducted with due diligence in February/March 2022. (Data on file at B. Braun)
- Ali RM et al J Am Coll Cardiol Intv 2019;12:558-66
- Scheller B et al. Circ Cardiovasc Interv. 2022 Sep;15(9):e012305.
- Ahmad WAW et al. JACC Cardiovasc Interv. 2022 Apr 11;15(7):770-779
- Clever et al. Circ Cardiovasc Interv. 2016 Apr;9(4):e003543.
- Kleber FX et al. Clin Res Cardiol. 2013 Nov;102(11):785-97.
- Jeger RV et JACC Cardiovasc Interv. 2020 Jun 22;13(12):1391-1402.
Take part in our customer survey
Your feedback matters! Participate in our customer survey to help us enhance our website, products and services. Thank you for your support!